Eldelumab

Eldelumab
Monoclonal antibody
Type	Whole antibody
Source	Human
Target	CXCL10/IP-10
Clinical data
ATC code	none;
Identifiers
CAS Number	946414-98-8;
ChemSpider	none;
UNII	15O91A27I5;
KEGG	D10404;
Chemical and physical data
Formula	C6502H10024N1736O2026S48
Molar mass	146468.72 g·mol−1

Eldelumab (alternative identifier BMS-936557^[1]) is a fully human monoclonal antibody (type IgG1 kappa)^[2] that targets chemokine (C-X-C motif) ligand 10 (CXCL10)/Interferon-γ-inducible protein-10 (IP-10)^[2]^[1] designed for the treatment of Crohn's disease and ulcerative colitis.^[3]

This drug was developed by

Bristol-Myers Squibb and Medarex.^[4]

References

^
PMID 26721935
.

^ ^a ^b "Anti-CXCL10 Therapeutic Antibody (eldelumab) - Creative Biolabs". www.creativebiolabs.net. Retrieved 2017-03-24.
^ Statement On A Nonproprietary Name Adopted By The USAN Council - Eldelumab, American Medical Association.
^ "Eldelumab". AdisInsight. Springer Nature Switzerland AG.

[Sandborn_2016-1] 
PMID 26721935
.

[:0-2] "Anti-CXCL10 Therapeutic Antibody (eldelumab) - Creative Biolabs". www.creativebiolabs.net. Retrieved 2017-03-24.

[3] Statement On A Nonproprietary Name Adopted By The USAN Council - Eldelumab, American Medical Association.

[4] "Eldelumab". AdisInsight. Springer Nature Switzerland AG.

[1]

[2]

[3]

[4]